Jacek Malyszko
Overview
Explore the profile of Jacek Malyszko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mucha K, Foroncewicz B, Debska-Slizien A, Durlik M, Grenda R, Horban A, et al.
Pol Arch Intern Med
. 2019 Oct;
129(Spec Issue 3):1-36.
PMID: 31593147
The 3 leading causes of death in patients after solid organ transplantation (SOT) include cardiovascular diseases, malignancies, and infections. According to our current understanding, the latter play the key role...
12.
Malyszko J, Malyszko M, Kozlowski L, Kozlowska K, Malyszko J
Oncotarget
. 2018 May;
9(29):20855-20871.
PMID: 29755695
Hypertension is one of the most common comorbidities in cancer patients with malignancy, in particular, in the elderly. On the other hand, hypertension is a long-term consequence of antineoplastic treatment,...
13.
Zawierucha J, Malyszko J, Malyszko J, Prystacki T, Marcinkowski W, Dryl-Rydzynska T
Przegl Lek
. 2018 Apr;
73(7):497-503.
PMID: 29677420
Secondary hyperparathyroidism
is one of the most common hormonal
disorders associated with a chronic
kidney disease. The main causes of
this disease are associated with renal
failure hyperphosphatemia, hypocalcemia,
and...
14.
Malyszko J, Kozlowski L, Kozlowska K, Malyszko M, Malyszko J
Oncotarget
. 2017 Oct;
8(39):66601-66619.
PMID: 29029541
A long time ago, the links between renal disease and malignancy were observed, however, quite recently, their importance was recognized and 'new' subspecialty in nephrology, namely 'onconephrology' was established. In...
15.
Malyszko J, Malyszko J
Pol Arch Intern Med
. 2017 Apr;
127(3):149-151.
PMID: 28377555
No abstract available.
16.
Malyszko J, Kozlowska K, Kozlowski L, Malyszko J
Nephrol Dial Transplant
. 2017 Mar;
32(6):924-936.
PMID: 28339935
Severe adverse systemic drug events occur commonly as a result of treatment of cancer patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication limiting the efficacy of the treatment. A...
17.
Zawierucha J, Malyszko J, Malyszko J, Dryl-Rydzynska T, Prystacki T, Marcinkowski W
Przegl Lek
. 2016 Aug;
73(4):229-32.
PMID: 27526425
Secondary hyperparathyroidism (sHPT) is a common complication being a consequence of metabolic disorders associated with chronic kidney disease (CKD). Treatment of the sHPT should lead to calcium-phosphate management stabilization and...
18.
Malyszko J, Koc-Zorawska E, Malyszko J
Transplant Proc
. 2014 Nov;
46(8):2651-3.
PMID: 25380887
Background: YKL-40 is an inflammatory glycoprotein involved in endothelial dysfunction and expressed in macrophages in the earliest lesion of atherosclerosis. Because cardiovascular mortality is the main cause of death, there...
19.
Malyszko J, Koc-Zorawska E, Matuszkiewicz-Rowinska J, Malyszko J
Transplant Proc
. 2014 Nov;
46(8):2647-50.
PMID: 25380886
Background: Fibroblast growth factor (FGF) 23 is a newly discovered member of the FGF family. Klotho is a cofactor of FGF23. Activation of the FGF23-Klotho system is responsible for negative...
20.
Malyszko J, Koc-Zorawska E, Levin-Iaina N, Malyszko J
Transplant Proc
. 2014 Nov;
46(8):2644-6.
PMID: 25380885
Background: In patients after kidney transplantation, anemia is relatively common and is associated with impaired kidney function, subclinical inflammatory state, and immunosuppressive treatment. Zonulin-prehaptoglobin-2, a newly discovered protein, is necessary...